Literature DB >> 30805642

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.

Zachary Miklja1, Amy Pasternak2, Stefanie Stallard1, Theodore Nicolaides3, Cassie Kline-Nunnally4, Bonnie Cole5, Rameen Beroukhim6, Pratiti Bandopadhayay6, Susan Chi6, Shakti H Ramkissoon7,8, Brendan Mullan1, Amy K Bruzek1, Angela Gauthier9, Taylor Garcia1, Christie Atchison1, Bernard Marini2, Maryam Fouladi10, D William Parsons11, Sarah Leary5, Sabine Mueller4, Keith L Ligon12, Carl Koschmann1.   

Abstract

As the field of neuro-oncology makes headway in uncovering the key oncogenic drivers in pediatric glioma, the role of precision diagnostics and therapies continues to rapidly evolve with important implications for the standard of care for clinical management of these patients. Four studies at major academic centers were published in the last year outlining the clinically integrated molecular profiling and targeting of pediatric brain tumors; all 4 demonstrated the feasibility and utility of incorporating sequencing into the care of children with brain tumors, in particular for children and young adults with glioma. Based on synthesis of the data from these studies and others, we provide consensus recommendations for the integration of precision diagnostics and therapeutics into the practice of pediatric neuro-oncology. Our primary consensus recommendation is that next-generation sequencing should be routinely included in the workup of most pediatric gliomas.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  high-grade glioma; low-grade glioma; next-generation sequencing; pediatric; precision medicine

Mesh:

Year:  2019        PMID: 30805642      PMCID: PMC6682212          DOI: 10.1093/neuonc/noz022

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  21 in total

Review 1.  Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.

Authors:  Kyle Wierzbicki; Karthik Ravi; Andrea Franson; Amy Bruzek; Evan Cantor; Micah Harris; Morgan J Homan; Bernard L Marini; Abed Rahman Kawakibi; Ramya Ravindran; Rodrigo Teodoro; Viveka Nand Yadav; Carl Koschmann
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

2.  MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.

Authors:  Giuseppina Catanzaro; Zein Mersini Besharat; Andrea Carai; Natalie Jäger; Elena Splendiani; Carole Colin; Agnese Po; Martina Chiacchiarini; Anna Citarella; Francesca Gianno; Antonella Cacchione; Evelina Miele; Francesca Diomedi Camassei; Marco Gessi; Luca Massimi; Franco Locatelli; David T W Jones; Dominique Figarella-Branger; Stefan M Pfister; Angela Mastronuzzi; Felice Giangaspero; Elisabetta Ferretti
Journal:  Biomark Res       Date:  2022-06-17

3.  What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry.

Authors:  Misa Matsuyama; Mythily Sachchithananthan; Robyn Leonard; Michael Besser; Anna K Nowak; Donna Truran; Claire M Vajdic; John R Zalcberg; Hui K Gan; Craig Gedye; Winny Varikatt; Eng-Siew Koh; Ganessan Kichenadasse; Hao-Wen Sim; Nicholas G Gottardo; Desma Spyridopoulos; Rosalind L Jeffree
Journal:  Neurooncol Pract       Date:  2021-08-31

4.  ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.

Authors:  Tingting Qin; Brendan Mullan; Ramya Ravindran; Dana Messinger; Ruby Siada; Jessica R Cummings; Micah Harris; Ashwath Muruganand; Kalyani Pyaram; Zachary Miklja; Mary Reiber; Taylor Garcia; Dustin Tran; Carla Danussi; Jacqueline Brosnan-Cashman; Drew Pratt; Xinyi Zhao; Alnawaz Rehemtulla; Maureen A Sartor; Sriram Venneti; Alan K Meeker; Jason T Huse; Meredith A Morgan; Pedro R Lowenstein; Maria G Castro; Viveka Nand Yadav; Carl Koschmann
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.995

Review 5.  Molecular alterations of low-grade gliomas in young patients: Strategies and platforms for routine evaluation.

Authors:  Iman Dandapath; Rituparna Chakraborty; Kavneet Kaur; Swati Mahajan; Jyotsna Singh; Mehar C Sharma; Chitra Sarkar; Vaishali Suri
Journal:  Neurooncol Pract       Date:  2021-08-23

6.  Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.

Authors:  Shahinda S R Alsayed; Amreena Suri; Anders W Bailey; Samuel Lane; Eryn L Werry; Chiang-Ching Huang; Li-Fang Yu; Michael Kassiou; Simone Treiger Sredni; Hendra Gunosewoyo
Journal:  RSC Med Chem       Date:  2021-08-23

Review 7.  Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.

Authors:  Tej D Azad; Michael C Jin; Lydia J Bernhardt; Chetan Bettegowda
Journal:  Neurosurg Focus       Date:  2020-01-01       Impact factor: 4.047

Review 8.  Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Carson S Hartlage; Santiago Haase; Syed Mohd Faisal; Rohit Thalla; Ali Dabaja; Kaushik Banerjee; Stephen V Carney; Anzar A Mujeeb; Michael R Olin; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.988

Review 9.  The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors.

Authors:  Tejus A Bale; Marc K Rosenblum
Journal:  Brain Pathol       Date:  2022-02-25       Impact factor: 7.611

10.  Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.

Authors:  Craig Erker; Adam Lane; Brooklyn Chaney; Sarah Leary; Jane E Minturn; Ute Bartels; Roger J Packer; Kathleen Dorris; Nicholas G Gottardo; Katherine E Warren; Alberto Broniscer; Mark W Kieran; Xiaoting Zhu; Peter White; Phillip J Dexheimer; Katie Black; Anthony Asher; Mariko DeWire; Jordan R Hansford; Sridharan Gururangan; Javad Nazarian; David S Ziegler; Eric Sandler; Allison Bartlett; Stewart Goldman; Chie-Schin Shih; Tim Hassall; Hetal Dholaria; Pratiti Bandopadhayay; Yvan Samson; Michelle Monje; Paul G Fisher; Andrew Dodgshun; Sarah Parkin; Murali Chintagumpala; Karen Tsui; David Gass; Valerie Larouche; Emmett Broxson; Mercedes Garcia Lombardi; Stacie Shiqi Wang; Jie Ma; Cynthia Hawkins; Dima Hamideh; Lars Wagner; Carl Koschmann; Christine Fuller; Rachid Drissi; Blaise V Jones; James Leach; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.